Aravive (ARAV) Competitors $0.04 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsSustainabilityTrends ARAV vs. PMCB, CHRO, TLPH, KPRX, KLTO, JAGX, BCLI, PHXM, CSCI, and AIMDShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry. Aravive vs. PharmaCyte Biotech Chromocell Therapeutics Talphera Kiora Pharmaceuticals Klotho Neurosciences Jaguar Health Brainstorm Cell Therapeutics PHAXIAM Therapeutics COSCIENS Biopharma Ainos PharmaCyte Biotech (NASDAQ:PMCB) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment. Which has preferable earnings & valuation, PMCB or ARAV? PharmaCyte Biotech has higher earnings, but lower revenue than Aravive. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharmaCyte BiotechN/AN/A$330K$0.533.32Aravive$9.14M0.32-$76.32MN/AN/A Is PMCB or ARAV more profitable? PharmaCyte Biotech's return on equity of 0.76% beat Aravive's return on equity.Company Net Margins Return on Equity Return on Assets PharmaCyte BiotechN/A 0.76% 0.45% Aravive N/A N/A N/A Does the media refer more to PMCB or ARAV? In the previous week, PharmaCyte Biotech's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score. Company Overall Sentiment PharmaCyte Biotech Neutral Aravive Neutral Does the MarketBeat Community prefer PMCB or ARAV? Aravive received 104 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users. CompanyUnderperformOutperformPharmaCyte BiotechN/AN/AAraviveOutperform Votes10462.28% Underperform Votes6337.72% Do institutionals & insiders believe in PMCB or ARAV? 34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAravive beats PharmaCyte Biotech on 4 of the 7 factors compared between the two stocks. Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / Sales0.32281.18434.4770.76Price / CashN/A65.9238.4235.17Price / BookN/A6.717.644.65Net Income-$76.32M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.54%-1.95%-2.68%1 Month PerformanceN/A-2.00%-0.23%-2.16%1 Year PerformanceN/A-5.04%16.69%12.90% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAraviveN/A$0.04flatN/AN/A$2.95M$9.14M0.0020High Trading VolumePMCBPharmaCyte BiotechN/A$1.63-0.6%N/A-14.6%$11.36MN/A3.084High Trading VolumeCHROChromocell TherapeuticsN/A$1.88+8.7%N/A-64.9%$11.33MN/A0.004TLPHTalphera2.5599 of 5 stars$0.65+2.7%$4.33+568.7%-50.8%$11.04M$650,000.00-0.9419Gap UpKPRXKiora Pharmaceuticals2.2239 of 5 stars$3.62+0.6%$10.00+176.2%-35.3%$10.86M$16M0.0010News CoverageKLTOKlotho NeurosciencesN/A$0.40+8.4%N/AN/A$10.83MN/A0.00N/AGap UpHigh Trading VolumeJAGXJaguar Health0.3072 of 5 stars$0.90+5.3%N/A-78.8%$10.62M$9.76M0.0050Gap UpBCLIBrainstorm Cell Therapeutics4.0518 of 5 stars$1.86+3.3%$30.00+1,512.9%-62.9%$10.60MN/A-0.3940Analyst ForecastNews CoveragePHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CSCICOSCIENS BiopharmaN/A$2.76-2.5%N/AN/A$10.43M$4.50M-0.2320AIMDAinos0.4108 of 5 stars$0.74+1.2%N/A-23.5%$10.41M$120,000.000.0040Gap Up Related Companies and Tools Related Companies PMCB Competitors CHRO Competitors TLPH Competitors KPRX Competitors KLTO Competitors JAGX Competitors BCLI Competitors PHXM Competitors CSCI Competitors AIMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARAV) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredThis quote from Elon says it all… (AI Breakthrough)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
